Science and Research

The prevalence of diagnosed alpha1-antitrypsin deficiency and its comorbidities: results from a large population-based database

alpha1-Antitrypsin deficiency (AATD) is a genetically determined disorder that is associated with different clinical manifestations. We aimed to assess the prevalence of diagnosed AATD and its comorbidities using a large healthcare database.In this retrospective longitudinal observational study, we analysed data from 4 million insurants. Using International Classification of Diseases revision 10 (ICD-10) codes, we assessed the prevalence, comorbidities and healthcare utilisation of AATD patients (E88.0 repeatedly coded) relative to non-AATD patients with chronic obstructive pulmonary disease (COPD), emphysema or asthma.In our study population, we identified 673 AATD patients (590 aged >/=30 years), corresponding to a prevalence of 23.73 per 100 000 in all age groups and 29.36 per 100 000 in those >/=30 years. Based on the number of AATD cases detected in the sample size (673 out of 2 836 585), we extrapolated that there were 19 162 AATD cases in Germany during the years studied. AATD patients had a higher prevalence of arterial hypertension, chronic kidney disease and diabetes relative to non-AATD asthma or emphysema patients. When compared to non-AATD COPD patients, AATD patients had significantly more consultations and more frequent and longer hospitalisations.Our data strengthen the assumption that AATD is associated with a variety of other diseases. Healthcare utilisation appears to be higher among AATD patients as compared to patients with non-AATD-related obstructive lung diseases.

  • Greulich, T.; Nell, C.; Hohmann, D.; Grebe, M.; Janciauskiene, S.; Koczulla, A. R.; Vogelmeier, C. F.
Publication details
DOI: 10.1183/13993003.00154-2016
Journal: The European respiratory journal
Number: 1
Work Type: Original
Location: BREATH
Disease Area: COPD
Partner / Member: MHH
Access-Number: 27824593
See publication on PubMed

DZL Engagements

chevron-down